Recent work has shown that blocking Notch signalling with the γ-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) reduces AAA incidence in the angiotensin II-induced mouse model (Cheng et al., 2023). This evidence concerns the gene AGT and triple-A syndrome.